Longboard Pharmaceuticals, Inc.
LBPHDelisted Dec 2, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001832168
Longboard Pharmaceuticals, Inc. was delisted on Dec 2, 2024; its insiders filed their last Form 4 on Dec 2, 2024; 125 institutions reported holding it in 13F filings for Q3 2024, worth $1.33B in total; Viking Global Investors was the only superinvestor holding it.
13F holders, Q2 2021
Institutional positions in Longboard Pharmaceuticals, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 17
- −5 vs. Q1 2021
- Shares held
- 7.98M
- −926.9K (−10.4%) vs. Q1 2021
- Total value
- $71.7M
- −$71.1M (−49.8%) vs. Q1 2021
- New holders
- 5
- 3 more added
- Sold out
- 10
- 6 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LBPH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 125 | $1.33B |
| Q2 2024 | 100 | $1.05B |
| Q1 2024 | 105 | $819.5M |
| Q4 2023 | 52 | $99.7M |
| Q3 2023 | 51 | $87.1M |
| Q2 2023 | 50 | $106.7M |
| Q1 2023 | 25 | $51.5M |
| Q4 2022 | 18 | $23.3M |
| Q3 2022 | 19 | $27.0M |
| Q2 2022 | 20 | $23.3M |
| Q1 2022 | 21 | $40.1M |
| Q4 2021 | 21 | $37.8M |
| Q3 2021 | 20 | $68.2M |
| Q2 2021 | 17 | $71.7M |
| Q1 2021 | 22 | $142.8M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Longboard Pharmaceuticals, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 2,321,403 | $20.9M | 0.81% | −34,597−1.5% | Reduced |
| Price T Rowe Associates Inc | 2,287,289 | $20.1M | 0.00% | −15,460−0.7% | Reduced |
| FMR LLC | 2,037,831 | $18.6M | 0.00% | +44,695+2.2% | Added |
| Farallon Capital Management, L.L.C. | 810,500 | $7.39M | 0.04% | 00.0% | Unchanged |
| Vanguard Group Inc | 165,545 | $1.51M | 0.00% | +110,545+201.0% | Added |
| OrbiMed Advisors LLC | 113,500 | $1.03M | 0.01% | −186,500−62.2% | Reduced |
| Alyeska Investment Group, L.P. | 85,360 | $778.0K | 0.01% | −39,640−31.7% | Reduced |
| Millennium Management LLC | 54,443 | $497.0K | 0.00% | −135,906−71.4% | Reduced |
| Integral Health Asset Management, LLC | 30,000 | $274.0K | 0.08% | 00.0% | Unchanged |
| Laurion Capital Management LP | 20,918 | $191.0K | 0.00% | −3,482−14.3% | Reduced |
| BlackRock Inc. | 17,999 | $164.0K | 0.00% | +17,999 | New |
| TD Asset Management Inc | 16,993 | $153.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 10,400 | $95.0K | 0.00% | +10,400 | New |
| UBS Group AG | 3,189 | $29.0K | 0.00% | +2,593+435.1% | Added |
| Advisory Services Network, LLC | 1,000 | $9.00K | 0.00% | +1,000 | New |
| Wells Fargo & Company | 33 | $0 | 0.00% | +33 | New |
| Tower Research Capital LLC (TRC) | 38 | $0 | 0.00% | +38 | New |
| Citigroup Inc | 0 | $0 | 0.00% | −405,645−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −181,473−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Davidson Kempner Capital Management LP | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Endurant Capital Management LP | 0 | $0 | 0.00% | −16,327−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −15,011−100.0% | Sold out |
| Wellington Management Group LLP | 0 | $0 | 0.00% | −11,333−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −10,606−100.0% | Sold out |
| Maven Securities LTD | 0 | $0 | 0.00% | −7,813−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −404−100.0% | Sold out |